Publications
- Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study2024 | Second Faculty of Medicine
- FCM marker importance for MRD assessment in T-cell acute lymphoblastic leukemia: An AIEOP-BFM-ALL-FLOW study group report2024 | Second Faculty of Medicine
- Patient specific real-time PCR in precision medicine - Validation of IG/TR based MRD assessment in lymphoid leukemia2023 | Second Faculty of Medicine
- Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study2022 | Second Faculty of Medicine
- DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch2021 | Second Faculty of Medicine
- Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia2019 | Second Faculty of Medicine
- Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy2019 | Second Faculty of Medicine
- Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection2017 | Second Faculty of Medicine
- Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia2017 | Second Faculty of Medicine
- The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL2015 | Second Faculty of Medicine
Loading network view...